WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients

International Journal of Molecular Sciences

Juan Chen²  Jiye Yin²  Xiangping Li²  Ying Wang⁴  Yi Zheng²  Chenyue Qian²  Ling Xiao²  Ting Zou²  Zhan Wang¹  Junyan Liu³  Wei Zhang²  Honghao Zhou²  Zhaoqian Liu² 

[1] Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China; E-Mail:;Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; E-Mails:;Xiangya School of Medicine, Central South University, Changsha 410008, China; E-Mail:;The Affiliated Cancer Hospital of XiangYa School of Medicine, Central South University, Changsha 410014, China; E-Mail:

关键词: WISP1;    lung cancer;    genetic polymorphism;    chemotherapy toxicity;   

DOI  :  10.3390/ijms151121011

来源: mdpi

【 摘 要 】

Platinum-based chemotherapy toxicity is always one of the serious problems from which lung cancer patients suffer. The genetic polymorphism of WISP1 was revealed to be associated with susceptibility and platinum-based chemotherapy response in our previous studies. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with platinum-based chemotherapy toxicity in lung cancer patients. A total of 412 lung cancer patients were enrolled in this study, and 28 polymorphisms of the WISP1 gene were genotyped by SequenomMassARRAY. We found that WISP1 polymorphisms (rs2929965, rs2929969, rs2929970, rs2929973 and rs754958) were related to the overall chemotherapy toxicity of lung cancer in subgroup analyses. Rs16904853, rs2929970, rs2977549 and rs2977551 (p = 0.021, 0.028, 0.024, 0.048, respectively) polymorphisms were significantly associated with hematologic toxicity. Rs2929946, rs2929970, rs2977519, rs2977536, rs3739262 and rs754958 (p = 0.031, 0.046, 0.029, 0.016, 0.042, 0.035, respectively) polymorphisms were significantly associated with the gastrointestinal toxicity of lung cancer. Genotypes of WISP1 may be novel and useful biomarkers for predicting platinum-based chemotherapy toxicity in lung cancer patients.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.